

Financial news for STML dated on 2020-05-13: Stemline Therapeutics 13D From A. Menarini Shows 5.2% Stake

Financial news for STML dated on 2020-05-05: Benzinga's Top Upgrades, Downgrades For May 5, 2020

Financial news for STML dated on 2020-05-05: Wedbush Downgrades Stemline Therapeutics to Neutral, Raises Price Target to \$12.5

Financial news for STML dated on 2020-05-05: 10 Biggest Price Target Changes For Tuesday

Financial news for STML dated on 2020-05-05: Ladenburg Thalmann Downgrades Stemline Therapeutics to Neutral, Announces \$12.5 Price Target

Financial news for STML dated on 2020-05-05: HC Wainwright & Co. Downgrades Stemline Therapeutics to Neutral, Lowers Price Target to \$12.5

Financial news for STML dated on 2020-05-05: 72 Biggest Movers From Yesterday

Financial news for STML dated on 2020-05-04: Benzinga's Top Upgrades, Downgrades For May 4, 2020

Financial news for STML dated on 2020-05-04: Mid-Afternoon Market Update: Crude Oil Gains 3%; Applied DNA Sciences Shares Spike Higher

Financial news for STML dated on 2020-05-04: Cantor Fitzgerald Earlier Downgraded Stemline Therapeutics to Neutral, Raised Price Target to \$12.5

Financial news for STML dated on 2020-05-04: 55 Stocks Moving In Monday's Mid-Day Session

Financial news for STML dated on 2020-05-04: Mid-Day Market Update: Pitney Bowes Slides Following Q1 Earnings; Stemline Therapeutics Shares Surge

Financial news for STML dated on 2020-05-04: Mid-Morning Market Update: Markets Mostly Lower; Tyson Foods Misses Q2 Expectations

Financial news for STML dated on 2020-05-04: Stemline Therapeutics To Go Private In \$667M Transaction

Financial news for STML dated on 2020-05-04: Stemline Therapeutics to be Acquired for \$11.50/Share Cash and Up to \$1/Share in Contingent Value Right by Menarini Group

Financial news for STML dated on 2020-03-31: 80 Biggest Movers From Yesterday

Financial news for STML dated on 2020-03-30: 55 Stocks Moving In Monday's Mid-Day Session

Financial news for STML dated on 2020-03-27: Cantor Fitzgerald Reiterates Overweight on Stemline Therapeutics, Lowers Price Target to \$10

Financial news for STML dated on 2020-03-26: JP Morgan Maintains Overweight on Stemline Therapeutics, Lowers Price Target to \$8

Financial news for STML dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for STML dated on 2020-03-17: Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to \$11

Financial news for STML dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for STML dated on 2020-03-17: HC Wainwright & Co. Maintains Buy on Stemline Therapeutics, Lowers Price Target to \$18

Financial news for STML dated on 2020-03-15: The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review

Financial news for STML dated on 2020-03-13: Stemline Therapeutics Q4 EPS \$(0.38) Up From \$(0.92) YoY, Sales \$11.8M

Financial news for STML dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for STML dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for STML dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for STML dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for STML dated on 2020-03-10: Stocks That Hit 52-Week Lows On Tuesday

Financial news for STML dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for STML dated on 2020-03-06: Stocks That Hit 52-Week Lows On Friday

Financial news for STML dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for STML dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for STML dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for STML dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for STML dated on 2020-01-21: H.C. Wainwright Reiterates Buy on Stemline Therapeutics, Lowers Price Target to \$20

Financial news for STML dated on 2020-01-16: Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to \$14

Financial news for STML dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for STML dated on 2020-01-15: 80 Biggest Movers From Yesterday

Financial news for STML dated on 2020-01-14: Mid-Afternoon Market Update: Dow Turns Lower; Stemline Therapeutics Shares Plummet

Financial news for STML dated on 2020-01-14: Mid-Day Market Update: GameStop Falls Following Soft 2019 Holiday Sales; RTI Surgical Shares Climb

Financial news for STML dated on 2020-01-14: 48 Stocks Moving In Tuesday's Mid-Day Session

Financial news for STML dated on 2020-01-14: Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q4 Expectations

Financial news for STML dated on 2020-01-14: The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

Financial news for STML dated on 2020-01-14: 26 Stocks Moving in Tuesday's Pre-Market Session

Financial news for STML dated on 2020-01-13: CORRECTION: Stemline Therapeutics Sees Q4 Sees Prelim. Q4 Net Revenues For ELZONRIS \$11.8M; A Prior Headline Indicated This Was The FY19 Estimate, This Was Incorrect

Financial news for STML dated on 2020-01-13: Stemline Therapeutics shares are trading lower after the company issued preliminary Q4 net revenues for ELZONRIS at \$11.8 million and \$43.2 million in FY19.

Financial news for STML dated on 2020-01-13: Stemline Therapeutics Sees Prelim. Q4 Net Revenues For ELZONRIS \$11.8M, Sees \$43.2M In FY19

Financial news for STML dated on 2019-12-24: Benzinga's Top Upgrades, Downgrades For December 24, 2019

Financial news for STML dated on 2019-12-24: Cantor Fitzgerald Initiates Coverage On Stemline Therapeutics with Overweight Rating, Announces \$18 Price Target

Financial news for STML dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for STML dated on 2019-12-06: Stemline Therapeutics Highlights Upcoming Presentations At ASH Dec. 7-10

Financial news for STML dated on 2019-11-11: Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to \$17

Financial news for STML dated on 2019-11-11: 80 Biggest Movers From Friday

Financial news for STML dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for STML dated on 2019-11-07: Stemline Therapeutics Q3 EPS \$(0.34) Beats \$(0.45) Estimate, Sales \$13.3M Miss \$13.64M Estimate

Financial news for STML dated on 2019-10-08: Stemline Therapeutics Announces ELZONRIS Clinical Data Selected For Oral Presentation At 81st Annual Meeting Of The Japanese Society Of Hematology

Financial news for STML dated on 2019-09-27: Stemline Therapeutics To Highlight SL-801 Data At ESMO

Financial news for STML dated on 2019-09-19: 52 Biggest Movers From Yesterday

Financial news for STML dated on 2019-09-18: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for STML dated on 2019-08-22: 60 Biggest Movers From Yesterday

Financial news for STML dated on 2019-08-09: 31 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for STML dated on 2019-08-08: Stocks That Set New 52-Week Highs Thursday

Financial news for STML dated on 2019-08-08: 52 Stocks Moving In Thursday's Pre-Market Session

Financial news for STML dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for STML dated on 2019-08-07: 42 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for STML dated on 2019-08-07: Stemline Therapeutics shares are trading lower after the company reported a 5 million share common stock offering.

Financial news for STML dated on 2019-08-07: Stemline Therapeutics Reports 5M Share Common Stock Offering

Financial news for STML dated on 2019-08-07: 85 Biggest Movers From Yesterday

Financial news for STML dated on 2019-08-06: Stemline Therapeutics Reports Centers For Medicare, Medicaid Services Granted New Technology Add-On Payment To ELZONRIS

Financial news for STML dated on 2019-08-05: 82 Biggest Movers From Friday

Financial news for STML dated on 2019-08-02: 60 Stocks Moving In Friday's Mid-Day Session

Financial news for STML dated on 2019-08-02: Stemline Therapeutics Q2 EPS \$(0.42) Up From \$(0.66) YoY, Sales \$13.007M Up From \$500K YoY

Financial news for STML dated on 2019-06-17: Stemline Therapeutics Announces Presentation of ELZONRIS Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

Financial news for STML dated on 2019-06-13: Stemline Therapeutics Highlights 3 Presentations Of ELZONRIS At European Hematology Association Congress

Financial news for STML dated on 2019-06-03: Stemline Therapeutics Highlights ASCO Presentation Of ELZONRIS Phase 2 Clinical Data In CMML And MF; Provides Next Steps For CMML Program

Financial news for STML dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for STML dated on 2019-05-20: Stemline Therapeutics Reports ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress

Financial news for STML dated on 2019-05-16: Stemline Therapeutics Highlights ELZONRIS Data Selected For Presentation At ASCO

Financial news for STML dated on 2019-05-13: Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock

Financial news for STML dated on 2019-05-13: Wedbush Downgrades Stemline Therapeutics, Inc. - Common Stock to Neutral

Financial news for STML dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for STML dated on 2019-05-10: Stemline Therapeutics Q1 EPS \$(0.73) Misses \$(0.63) Estimate, Sales \$5.049M Beat \$2.36M Estimate

Financial news for STML dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for STML dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for STML dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for STML dated on 2019-03-18: 7 Stocks To Watch For March 18, 2019

Financial news for STML dated on 2019-03-15: Stemline Therapeutics Q4 EPS \$(0.92) Misses \$(0.74) Estimate

Financial news for STML dated on 2019-03-13: 56 Biggest Movers From Yesterday

Financial news for STML dated on 2019-03-11: Stemline Therapeutics Licenses Worldwide Rights to a Novel Selective RET Inhibitor

Financial news for STML dated on 2019-01-30: Stemline Therapeutics Announces Validation Of Marketing Authorization Application By The European Medicines Agency

Financial news for STML dated on 2019-01-16: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for STML dated on 2019-01-16: 55 Biggest Movers From Yesterday

Financial news for STML dated on 2019-01-16: Stemline Therapeutics Prices Upsized 8.8M Share Public Offering of Common Stock @\$9/Share

Financial news for STML dated on 2019-01-15: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for STML dated on 2019-01-15: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for STML dated on 2019-01-14: 6 Stocks Moving In Monday's After-Hours Session

Financial news for STML dated on 2019-01-14: Stemline Therapeutics shares are trading lower after the company announced an offering of 6.6 million shares of common stock.

Financial news for STML dated on 2019-01-14: Stemline Therapeutics Reports Offering Of 6.6M Shares Of Common Stock

Financial news for STML dated on 2019-01-07: Stemline Therapeutics Announces Submission Of European Marketing Authorization Application For ELZONRIS

Financial news for STML dated on 2018-12-27: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for STML dated on 2018-12-26: Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation

Financial news for STML dated on 2018-12-21: Stemline Therapeutics Issues Press Release Confirming FDA Approval OF ELZONRIS For Treatment Of Blastic Plasmacytoid Dendritic Cell Neoplasm

Financial news for STML dated on 2018-12-21: FDA Approves Stemline Therapeutics' ELZONARIS Infusion For Treatment Of Blastic Plasmacytoid Dendritic Cell Neoplasm

Financial news for STML dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for STML dated on 2018-12-11: JP Morgan Initiates Coverage On Stemline Therapeutics with Overweight Rating

Financial news for STML dated on 2018-11-30: Stemline Therapeutics Option Alert: Jan 18 \$10 Calls at the Ask: 680 @ \$1.7 vs 651 OI; Ref=\$10.6851

Financial news for STML dated on 2018-11-30: The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings

Financial news for STML dated on 2018-11-29: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018

Financial news for STML dated on 2018-11-28: 48 Biggest Movers From Yesterday

Financial news for STML dated on 2018-11-26: Benzinga's Top Upgrades, Downgrades For November 26, 2018

Financial news for STML dated on 2018-11-26: PiperJaffray Initiates Coverage On Stemline Therapeutics with Overweight Rating

Financial news for STML dated on 2018-11-25: The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

Financial news for STML dated on 2018-11-23: 50 Biggest Movers From Wednesday

Financial news for STML dated on 2018-11-20: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018

Financial news for STML dated on 2018-11-20: The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

Financial news for STML dated on 2018-11-20: Stemline Therapeutics Announces EMA Grants Accelerated Assessment For Planned Elzonris Marketing Authorization Application

Financial news for STML dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for STML dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for STML dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for STML dated on 2018-11-08: Stemline Therapeutics Q3 EPS \$(0.73) Misses \$(0.67) Estimate

Financial news for STML dated on 2018-09-05: Court Filing Shows A US Judge Has Blocked State Of Texas's Fetal Tissue Burial Law

Financial news for STML dated on 2018-08-13: Benzinga Pro's 5 Stocks To Watch Today

Financial news for STML dated on 2018-08-13: Stemline Therapeutics Announces that FDA Accepts ELZONRIS Biologics License Application and Grants Priority Review

Financial news for STML dated on 2018-08-09: Stemline Therapeutics Q2 EPS \$(0.66) Misses \$(0.64) Estimate

Financial news for STML dated on 2018-06-25: Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS

Financial news for STML dated on 2018-06-18: Stemline Therapeutics Reports Clinical Data from ELZONRISTM Trials in BPDCN, CMMML and MF Delivered at the EHA Congress

Financial news for STML dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for STML dated on 2018-06-05: Stemline Therapeutics Announces Positive Data Presentations On SL-701 And SL-801 At ASCO

Financial news for STML dated on 2018-06-03: The Week Ahead In Biotech: ASCO

Presentations Dominate The Headlines

Financial news for STML dated on 2018-05-11: Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again

Financial news for STML dated on 2018-05-09: Stemline Therapeutics Q1 EPS \$(0.69), Inline

Financial news for STML dated on 2018-04-05: Stemline Therapeutics Reports Start of Rolling BLA Submission for SL-401

Financial news for STML dated on 2018-03-16: Stemline Therapeutics Reports Q4 EPS \$(0.93) Misses \$(0.70) Est., No Sales

Financial news for STML dated on 2018-01-24: Stemline Therapeutics Prices 3.7M Share Common Stock Offering At \$14/Share

Financial news for STML dated on 2018-01-22: Stemline Therapeutics Announces 3.7M Shares Common Stock Offering

Financial news for STML dated on 2017-12-13: Stemline Therapeutics Offers SL-401 Phase 1/2 Trial Outcomes For MPN, AML

Financial news for STML dated on 2017-12-13: UPDATE: Stemline Says BLA Submission Preparation For SL-401 Underway

Financial news for STML dated on 2017-12-13: Stemline Therapeutics Reports Presentation Of Detailed SL-401 Pivotal Data At ASH: Primary Endpoint In BPDCN Met, Median Overall Survival Not Reached In First-Line Patients

Financial news for STML dated on 2017-12-08: Stemline Therapeutics Highlights Will Offer 4 SL-401 Presentations At ASH

Financial news for STML dated on 2017-11-09: Stemline Therapeutics Reports Q3 EPS \$(0.68) vs. \$(0.61) Est., \$299.4K vs. \$170K Est.

Financial news for STML dated on 2017-11-01: 46 Biggest Movers From Yesterday

Financial news for STML dated on 2017-10-31: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for STML dated on 2017-10-31: Stemline Therapeutics Shares Hit A High Of \$12.54 Premarket On Report That Co. Met Primary Endpoint In SL-401 Trial, Shares Have Since Pulled Back From Premarket Highs To \$10.94, Up 3.7%

Financial news for STML dated on 2017-08-08: Stemline Therapeutics Q2 EPS \$(0.66) vs \$(0.48) Est., Sales \$299.4K vs \$200.0K Est.

Financial news for STML dated on 2017-06-23: 15 Biggest Mid-Day Gainers For Friday

Financial news for STML dated on 2017-06-23: Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN

Financial news for STML dated on 2017-06-23: Stemline Therapeutics Expected To Deliver Update On Phase 2 Data For SL-401 at EHA Today

Financial news for STML dated on 2017-06-19: Companies Holding Shareholder Meetings Today Include Monster Beverage, Stemline Therapeutics, and Century Aluminum

Financial news for STML dated on 2017-06-16: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for STML dated on 2017-05-18: Stemline Therapeutics to Present SL-401 Updated Data from Stage 1d 2 of Ongoing Pivotal Phase 2 BPDCN Trial at EHA Meeting; Says Remains On Track to Provide Update on BPDCN Patients Enrolled in Stage 3 of Phase 2 Pivotal Trial in H2 of This Year

Financial news for STML dated on 2017-05-10: Stemline Therapeutics Reports Q1 EPS \$(0.67) vs \$(0.47) Est., Grant Sales \$299.4K vs \$150K Est.

Financial news for STML dated on 2017-03-23: Expect Stemline To Generate Acquisition Interest As SL-401 Approval Decision Nears

Financial news for STML dated on 2017-02-06: 7 Biggest Price Target Changes For Monday

Financial news for STML dated on 2017-02-06: Why A Patient Death Doesn't Necessarily Scuttle Stemline's Chances For SL-401 Approval

Financial news for STML dated on 2017-02-03: A First Take On Stemline's Pivotal BPDCN Study Patient Death

Financial news for STML dated on 2017-02-03: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for STML dated on 2017-02-02: Adam Feuerstein Tweets: \$STML confirms it received report of patient death on Jan. 18. But co. DID NOT disclose death to investors who bought their deal on Jan. 19.

Financial news for STML dated on 2017-02-02: Stemline Therapeutics Provides Update on Pivotal BPDCN Trial, Says Co. Received A Report Of Patient Death On Jan. 18th Due To CLS Which Is A Side Effect Of SL-401

Financial news for STML dated on 2017-02-02: Cowen Defending Stemline, Says Today's Move Is Huge Overreaction, Says Ontak's Label Has Black Box Warning For CLS And Mentions Cases Of Death Due To CLS, Yet FDA Didn't Pull Drug Off Market

Financial news for STML dated on 2017-02-02: 18 Biggest Mid-Day Losers For Thursday

Financial news for STML dated on 2017-02-02: Adam Feuerstein @adamfeuerstein Tweet: Side Effect Kills Cancer Patient in \$STML Drug Trial, the Company Raises Money thestreet.com/story/13975695

Financial news for STML dated on 2017-01-20: 15 Biggest Mid-Day Losers For Friday

Financial news for STML dated on 2017-01-20: Stemline Therapeutics Prices Offering Of 4.5M Shares At \$10/Share

Financial news for STML dated on 2017-01-20: Hearing Stemline Therapeutics Offering of 3.2M Shares Priced at \$10/Share

Financial news for STML dated on 2017-01-20: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for STML dated on 2017-01-19: Stemline Therapeutics Reports Proposed Public Offering of Common Stock

Financial news for STML dated on 2017-01-06: Mid-Afternoon Market Update: AZZ Drops On Weak Q3 Results; Stemline Shares Spike Higher

Financial news for STML dated on 2017-01-06: 15 Biggest Mid-Day Gainers For Friday

Financial news for STML dated on 2017-01-06: Mid-Day Market Update: Dow Gains 50 Points; Ruby Tuesday Shares Fall Following Q2 Results

Financial news for STML dated on 2017-01-06: Mid-Morning Market Update: Markets Mixed; Greenbrier Profit Misses Views

Financial news for STML dated on 2017-01-06: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for STML dated on 2017-01-05: UPDATE: Stemline Says BLA Filing is Targeted for 2H'17, Commercial Launch Projected for '18

Financial news for STML dated on 2017-01-05: UPDATE: Stemline Says Apprx. Half of New Cohort Patients Already Enrolled, Full Enrollment Expected This Qtr.

Financial news for STML dated on 2017-01-05: Stemline Reports FDA Deal on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN

Financial news for STML dated on 2016-12-06: Stemline Therapeutics Reports Results from Ongoing Phase 2 Trial in AML in Remission with MRD: SL-401 Found to be Safe, Well Tolerated, Side Effects Predictable, Manageable

Financial news for STML dated on 2016-12-05: American Society Of Hematology (ASH) Meeting Presenters Tonight Include Karyopharm, bluebird bio, Alnylam, Juno Therapeutics, Stemline Therapeutics, Kite Pharma, Beigene, & Prothena

Financial news for STML dated on 2016-12-02: American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4

Financial news for STML dated on 2016-11-08: Stemline Therapeutics Reports Q3 EPS \$(0.56) vs \$(0.54) Est., Sales \$299.401K vs \$180K Est.

Financial news for STML dated on 2016-10-11: Stocks Hitting 52-Week Highs

Financial news for STML dated on 2016-09-29: 15 Stocks That Rallied 4 Days, Then Sold Off Yesterday

Financial news for STML dated on 2016-08-31: 15 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for STML dated on 2016-08-23: Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401

Financial news for STML dated on 2016-08-04: Stemline Therapeutics Reports Q2 EPS \$(0.52) vs. Est. \$(0.55)

Financial news for STML dated on 2016-06-04: Stemline Therapeutics Announces SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at #ASCO16; Says High Response Rates Demonstrated Across All Lines As Enrollment Proceeds

Financial news for STML dated on 2016-05-19: Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Selected for Oral Presentations at the Upcoming ASCO, EHA Meetings

Financial news for STML dated on 2016-05-09: Stemline Therapeutics Q1 EPS (\$0.51) vs (\$0.59) est, Revenue \$205.65K vs \$150.00K est

Financial news for STML dated on 2016-03-14: Stemline Therapeutics Reports Q4 EPS \$(0.58) vs. Est. \$(0.57)

Financial news for STML dated on 2015-12-22: Stemline Therapeutics Reports Opening of SL-801 IND

Financial news for STML dated on 2015-12-07: Stemline Therapeutics Presents Clinical Update From Ongoing SL-401 Pivotal BPDCN Trial, Produced 86% Overall Response Rate

Financial news for STML dated on 2015-12-04: Stemline Reports Five Presentations, Will Offer Update on SL-401 Trial from Ongoing Pivotal BPDCN Trial at ASH Meeting

Financial news for STML dated on 2015-09-10: Stemline Reports EU Orphan Drug Designation for SL-401 for Treatment of Acute Myeloid Leukemia

Financial news for STML dated on 2015-08-10: Stemline Therapeutics Reports Q2 Loss \$0.58 Vs Est Loss \$0.41, Sales \$121.4K Vs Est \$80.0K

Financial news for STML dated on 2015-05-28: Stemline Therapeutics Offers Top-Line Results from Lead-In Stage of Ongoing BPDCN Pivotal Trial: Says SL-401 Showed Multi-Cycle Safety, Efficacy

Financial news for STML dated on 2015-05-11: Stemline Therapeutics Reports Q1 Loss of \$0.46/Share vs Loss of \$0.43/Share Est.

Financial news for STML dated on 2015-04-27: HC Wainwright Initiates Stemline Therapeutics At Buy

Financial news for STML dated on 2015-04-27: H.C. Wainwright Initiates Stemline Therapeutics With Buy

Financial news for STML dated on 2015-04-27: Benzinga's Top Initiations

Financial news for STML dated on 2015-04-27: H.C. Wainwright Initiates Coverage on Stemline Therapeutics at Buy, Announces \$38.00 PT

Financial news for STML dated on 2015-02-23: Biotech Stocks Moving Higher

Financial news for STML dated on 2015-02-03: Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results

Financial news for STML dated on 2015-01-30: Stemline Therapeutics Announces SL-701 Granted Orphan Drug Designation for the Treatment of Glioma

Financial news for STML dated on 2015-01-13: What Investors Are Looking At In The Stem Cell Sector

Financial news for STML dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Financial news for STML dated on 2015-01-08: Mid-Morning Market Update: Markets Jump; Family Dollar Profit Misses Estimates

Financial news for STML dated on 2015-01-08: Morning Market Losers

Financial news for STML dated on 2015-01-08: Stemline Therapeutics Prices 3.8M Shares at \$15.75/Share

Financial news for STML dated on 2015-01-07: Stemline Therapeutics Announces Public

Offering of Common Stock

Financial news for STML dated on 2015-01-07: Stemline Therapeutics In-Licenses Novel Oral Small Molecule Nuclear Transport Inhibitor Targeting XP01

Financial news for STML dated on 2014-12-31: What Investors Are Looking For In Brainstorm Cell Therapeutics' Upcoming Clinical Results

Financial news for STML dated on 2014-12-16: Stemline Therapeutics Initiates SL-401 Clinical Trial In Four Rare Myeloproliferative Neoplasms

Financial news for STML dated on 2014-11-12: Stemline Therapeutics Reports Q3 EPS of \$(0.53) vs \$(0.58) Est

Financial news for STML dated on 2014-10-16: Stemline Therapeutics Initiates SL-401 Trial In AML Patients In First Complete Response With Minimal Residual Disease, The Second SL-401 Trial Initiated In 2H14

Financial news for STML dated on 2014-09-03: Stemline Therapeutics Chairman Bergstein Buys 2,000 Shares @\$11.05/Share -Form 4

Financial news for STML dated on 2014-08-14: Stemline Therapeutics Reports Q2 EPS of \$(0.47) vs \$(0.69) Est

Financial news for STML dated on 2014-06-17: Events Scheduled for Week of Jun. 16th to Jun. 20th

Financial news for STML dated on 2014-05-20: Stemline Therapeutics Announces Presentation of SL-401 Preclinical Efficacy Data in Multiple Myeloma at ASCO

Financial news for STML dated on 2014-04-08: US Stock Futures Drop; Alcoa Earnings In Focus

Financial news for STML dated on 2014-04-08: Stemline Therapeutics Announces FDA Acceptance of IND for SL-701

Financial news for STML dated on 2014-04-08: Stemline Therapeutics Announces FDA Acceptance of IND for SL-701

Financial news for STML dated on 2014-04-03: Amended 13G Filing from SAC Capital on Stemline Therapeutics Shows Reduced Stake from 5.39% as of Dec. 31st to 2.7%

Financial news for STML dated on 2014-04-01: Stemline Therapeutics to Present SL-501 Preclinical Efficacy Data in TKI-Resistant CML at AACR

Financial news for STML dated on 2014-02-03: Stemline Therapeutics Files \$150M Mixed Securities Shelf

Financial news for STML dated on 2013-11-23: Stemline Therapeutics Present Clinical Trial Results of Synthetic Peptide Vaccine for Brain Cancer at SNO Annual Meeting

Financial news for STML dated on 2013-11-19: Stemline Therapeutics Reports Clinical Trial Results w SL-701

Financial news for STML dated on 2013-11-13: UPDATE: Aegis Capital Reiterates on Stemline Therapeutics Ahead of ASH Annual Meeting

Financial news for STML dated on 2013-10-30: Stemline Therapeutics Shares Spike Higher; May be Attributed to Aegis Capital Raising PT from \$40 to \$70

Financial news for STML dated on 2013-10-23: Stemline Therapeutics Spikes Higher

Financial news for STML dated on 2013-10-23: Stemline Files to Withdraw S-1 for Offering

Financial news for STML dated on 2013-09-12: UPDATE: Wedbush Initiates Coverage on Stemline Therapeutics on Strong SL-401 Potential

Financial news for STML dated on 2013-09-12: Wedbush Initiates Coverage on Stemline Therapeutics at Outperform, Announces \$49.00 PT

Financial news for STML dated on 2013-09-11: Wedbush Initiates Coverage on Stemline Therapeutics at Outperform, Announces \$49.00 PT

Financial news for STML dated on 2013-08-29: Benzinga's Top Initiations

Financial news for STML dated on 2013-08-29: UPDATE: Jefferies Initiates Coverage on Stemline Therapeutics Ahead of SL-401 Trials

Financial news for STML dated on 2013-08-29: Jefferies Initiates Coverage on Stemline Therapeutics at Buy, Announces \$60.00 PT

Financial news for STML dated on 2013-07-30: Benzinga's Top Initiations

Financial news for STML dated on 2013-07-30: Roth Capital Initiates Coverage on Stemline Therapeutics at Buy, Announces \$50.00 PT

Financial news for STML dated on 2013-07-01: Stemline Therapeutics Added to Russell 3000(R) Index

Financial news for STML dated on 2013-06-21: Aegis Capital Maintains Buy on Stemline Therapeutics, Raises PT to \$40.00

Financial news for STML dated on 2013-06-21: UPDATE: Aegis Capital Raises PT on Stemline Therapeutics Following Recent Progress

Financial news for STML dated on 2013-06-18: Ladenburg Thalmann Initiates Coverage on Stemline Therapeutics at Buy, Announces \$36.00 PT

Financial news for STML dated on 2013-06-13: Stocks Hitting 52-Week Highs

Financial news for STML dated on 2013-05-22: Stemline Therapeutics Closes \$60M Offering of Common Shares

Financial news for STML dated on 2013-05-16: Stemline Therapeutics Prices 4.1M Shares at \$14.50/Share

Financial news for STML dated on 2013-03-18: Aegis Capital Initiates Stemline Therapeutics at Buy on Attractive Valuation

Financial news for STML dated on 2013-03-18: Aegis Capital Initiates Coverage on Stemline Therapeutics at Buy, Announces \$35.00 PT

Financial news for STML dated on 2013-02-12: WBB Securities Initiates Coverage on Stemline Therapeutics at Sell, Announces \$9.00 PT

Financial news for STML dated on 2013-02-01: Stocks Hitting 52-Week Lows

Financial news for STML dated on 2013-01-29: Stemline Therapeutics Shares Open for Trade ~\$11.30, Priced at \$10

Financial news for STML dated on 2013-01-08: Stemline Therapeutics Raises IPO Share Amount from 1.82M Shares to 2.275M Shares, Price Will Be in \$10-12/Share Range